Sign up to save your podcasts
Or
Share Beyond IOP: Integrating Ocular Surface Resilience Into Glaucoma Management
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Beyond IOP: Integrating Ocular Surface Resilience Into Glaucoma Management
CME credits: 1.00
Valid until: 20-04-2027
Claim your CME credit at https://reachmd.com/programs/cme/beyond-iop-integrating-ocular-surface-resilience-into-glaucoma-management/49097/
Glaucoma care is shifting from a narrow focus on pressure targets to a broader, patient-centered approach that balances durable intraocular pressure (IOP) control with preservation of the ocular surface, comfort, and real-world adherence. But, daily practice often still defaults to drop-heavy regimens that can erode the very ocular surface on which long-term success depends. The chronic use of preserved topical medications can compromise the cornea and conjunctiva, perpetuating ocular surface disease (OSD) and ocular surface inflammation (OSI). These conditions not only degrade comfort and quality of life but also undermine adherence, accelerate treatment failure, and reduce the success rates of both medical and surgical interventions. Recent expert consensus underscores that every glaucoma patient should be screened for OSD/OSI, yet implementation remains inconsistent in daily practice. Contemporary perspectives and data support a shift toward ocular surface-sparing strategies, including preservative-free options, earlier laser strategies, and newer tear-restorative, anti-inflammatory, and neuromodulatory therapeutic options when OSD does occur.
=
View all episodes
By ReachMD
4.3
33 ratings
CME credits: 1.00
Valid until: 20-04-2027
Claim your CME credit at https://reachmd.com/programs/cme/beyond-iop-integrating-ocular-surface-resilience-into-glaucoma-management/49097/
Glaucoma care is shifting from a narrow focus on pressure targets to a broader, patient-centered approach that balances durable intraocular pressure (IOP) control with preservation of the ocular surface, comfort, and real-world adherence. But, daily practice often still defaults to drop-heavy regimens that can erode the very ocular surface on which long-term success depends. The chronic use of preserved topical medications can compromise the cornea and conjunctiva, perpetuating ocular surface disease (OSD) and ocular surface inflammation (OSI). These conditions not only degrade comfort and quality of life but also undermine adherence, accelerate treatment failure, and reduce the success rates of both medical and surgical interventions. Recent expert consensus underscores that every glaucoma patient should be screened for OSD/OSI, yet implementation remains inconsistent in daily practice. Contemporary perspectives and data support a shift toward ocular surface-sparing strategies, including preservative-free options, earlier laser strategies, and newer tear-restorative, anti-inflammatory, and neuromodulatory therapeutic options when OSD does occur.
=